PureTech receives orphan drug designations for IPF treatment Feb 19, 2026 12:37PM
PureTech Health Plc (PRTC) Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone Oct 22, 2025 04:44AM
PureTech launches Celea to advance lung fibrosis drug Aug 21, 2025 07:01AM
PureTech launches Celea Therapeutics for respiratory disease treatments Aug 12, 2025 07:01AM
PureTech Health chairman Raju Kucherlapati steps down from board Jul 8, 2025 12:45PM


Apr 7, 2025 12:22PM PureTech Health Plc (PRTC) confirms it is in discussions with Nordic Capital
Mar 11, 2025 07:06AM PureTech Health Plc (PRTC) Appoints Robert J. Hombach to its Board
Feb 12, 2025 07:05AM PureTech (PRTC) Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with Glyp
Dec 16, 2024 02:39PM PureTech Health (PRTC) PT Raised to $46 at Leerink Partners
Sep 27, 2024 06:54AM PureTech Health Plc (PRTC) -Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Sep 9, 2024 12:10PM Leerink Partners Assumes PureTech Health (PRTC) at Outperform, 'we think PRTC’s Founded Entities could be relevant value drivers'
Aug 13, 2024 07:06AM PureTech Health-founded (PRTC) Seaport Therapeutics Appoints David Wheadon to its Board
Jun 20, 2024 05:45AM PureTech Health Plc (PRTC) Appoints Raju Kucherlapati as Board Chair
Jun 18, 2024 07:06AM PureTech Health Plc (PRTC) Founded Entity Seaport Therapeutics Appoints Management Executives